NEUROTECHNOLOGY INDUSTRY REPORTS RECORD GLOBAL GROWTH OF $144.5 BILLION IN 2008

SAN FRANCISCO, May 12, 2009 -- NeuroInsights, the neurotech market authority, announced the release of the organization's fifth annual comprehensive investment guide and market analysis of the global neurological disease and psychiatric illness markets. Unveiled during the annual Neurotech Industry Investing and Partnering Conference in San Francisco, this 480-page report enables investors, companies and governments to assess opportunities, calculate risks and understand the dynamics of this continually changing market.

"The neurotechnology industry faced many challenges in 2008.  The deep recession has put many development stage companies in this sector at risk," said Casey Lynch, Managing Director of NeuroInsights. "Nonetheless, commercial neuroscience represents one of the fastest-growing and critically needed sectors of the healthcare industry.  The opportunities are massive and apparent in the continued strong revenue growth in both neuropharmaceuticals and neurodevices.”

Specific findings from the Neurotechnology Industry 2009 Report show that in 2008:

- Brain-related illnesses are the largest unmet medical market with two billion people worldwide
- Venture capital investment in neurotechnology was down 22% to $1.44 billion
- More than 250 venture investors participated in neurotech financings in 2008
- Global Neurotech industry revenues rose 9.0% to $144.5 billion
- Neuropharmaceuticals recorded revenues of $121.6 billion and 9.3% annual growth
- Neurodevices recorded revenues of $6.1 billion and 18.6% annual growth
- Neurodiagnostics recorded revenues of $16.8 billion and 4% annual growth

Specific milestones from the report were presented during the 4th annual Neurotech Industry Investing and Partnering Conference, co-hosted by the Neurotechnology Industry Organization and NeuroInsights. This conference, was held at the St. Regis San Francisco today and tomorrow, is the premier global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.

“The record number of attendees at this meeting is a testament to the high level of investor interest and clinical progress being made across neurotechnology,” said Zack Lynch. “With over 2 billion people worldwide suffering from a neurological disease, psychiatric illness or nervous system injury, this continued momentum can not come fast enough.”

The Neurotechnology Industry 2009 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System tracks market movements that help guide strategic business development and investment decisions in neurotech. This year’s report provides an in-depth look at more than 16 brain and nervous system disorders and treatments in development at over 550 public and private companies, including: Alzheimer's disease, addiction, ADHD, anxiety, depression, epilepsy, migraine, mild cognitive impairment, multiple sclerosis, obesity, pain, Parkinson's disease, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, stroke and traumatic brain injury. Corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry are fully assessed with detailed insights.

The Neurotechnology Industry 2009 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System is now available for purchase in hard copy or pdf format at http://www.neuroinsights.com/marketreports/marketreport2009.html